Privacy Policy

Clinical Trial Media, Inc. (“CTM”)

Privacy Policy

Effective January 22, 2021

INTRODUCTION  

CTM is committed to respecting and protecting your privacy.

This privacy policy sets out how we look after your personal data, how we will use your personal data, and tells you about your privacy rights and how the law protects you.

This privacy policy sets out our approach to protecting personal data on a worldwide basis and we recognize that different jurisdictions and legal systems will apply:

  1. In the United States, the Federal Trade Commission has jurisdiction over our compliance regarding personal data. If you do not agree to the terms of this privacy policy, you should not access or use any CTM website or service.
  2. In the rest of the world, different legal rules apply and, in particular, we will be using and protecting personal data in a way which is in accordance with the rules operating in the European Economic Area (“EEA”) which has adopted the General Data Protection Regulation (“GDPR”) and the United Kingdom (“UK”) which has adopted its own version of the GDPR. In the EEA or UK, the relevant national supervisory authority will have jurisdiction over our compliance in the relevant country. If you do not agree to the terms of this privacy policy, please do not access or use any CTM website or service.

TABLE OF CONTENTS

  1. PURPOSE
  2. THE DATA WE COLLECT ABOUT YOU
  3. HOW YOUR PERSONAL DATA IS COLLECTED
  4. HOW WE USE AND DISCLOSE YOUR PERSONAL DATA
  5. INTERNATIONAL TRANSFERS
  6. DATA SECURITY
  7. DATA RETENTION
  8. YOUR DATA PRIVACY RIGHTS UNDER GDPR AND UK PRIVACY LAW
  9. YOUR CALIFORNIA PRIVACY RIGHTS
  10. DEFINITIONS

1.  PURPOSE  

This privacy policy describes how CTM collects, uses, processes and protects your personal data and informs the choices available to you regarding how you can choose and manage your personal data.

It is important that you read this privacy policy together with any other privacy policy or fair processing notice we may provide on specific occasions when we are collecting or processing personal data about you so that you are fully aware of how and why we are using your data. This privacy policy supplements the other notices and is not intended to override them.

1.1 CONTROLLER  

This privacy policy is issued on behalf of CTM so when “we”, “us” or “our” is mentioned in this privacy policy, we are responsible for processing your data. 

We have appointed a data protection officer who is responsible for dealing with questions in relation to this privacy policy. If you have any questions about this privacy policy, including any requests to exercise your legal rights, please contact the data protection officer using the details set out below.

1.2 CONTACT DETAILS  

Our contact details for privacy rights requests and information about our privacy practices are:

Full name of legal entity: Clinical Trial Media, Inc.

Name or title of data protection officer: Richard Cudmore

Email address: privacy@clinicaltrialmedia.com

Telephone number: 516-470-0720

Postal address: 100 Motor Parkway, Suite 528, Hauppauge, NY 11788, USA

URL: https://clinicaltrialmedia.com/request-form/ 

1.3 COMPLAINTS 

You have the right to make a complaint at any time to the relevant national supervisory authority in the country where you reside. To find more about this right and to locate the appropriate Data Privacy Authority, go to the European Commission website (https://ec.europa.eu/info/policies/justice-and-fundamental-rights_en) if in the UK, go to the Information Commissioner’s Office (“ICO”) website (www.ico.org.uk). If you are in the United States, you may contact the US Federal Trade Commission regarding your concerns. For more information, please see https://www.ftc.gov/faq/consumer-protection/submit-consumer-complaint-ftc.  

We would, however, appreciate the chance to deal with your concerns before you approach one of the national supervisory authorities, so please contact us in the first instance.

1.4 CHANGES TO THE PRIVACY POLICY AND YOUR DUTY TO INFORM US OF CHANGES IN YOUR PERSONAL DATA  

We reserve the right to amend this privacy policy and will notify you by updating this notice, so please check it from time to time, especially if you have ongoing dealings with us. It is important that the personal data we hold about you is accurate and current. Please keep us informed if your personal data changes during your relationship with us.

1.5 THIRD-PARTY LINKS  

This website may include links to third-party websites, plug-ins and applications. Clicking on those links or enabling those connections may allow third parties to collect or share data about you. We do not control these third-party websites and are not responsible for their privacy statements. When you leave our website, we encourage you to read the privacy policy of every website you visit

 2.  THE DATA WE COLLECT ABOUT YOU  

Personal data, or personal information, means any information related to an identified or identifiable natural person. It does not, however, include data where the identity has been removed (anonymized data).

We may collect, use, store and transfer different categories of personal data about you which we have grouped together as follows:

  • Identity Data includes first name, maiden name, last name, username or similar identifier, date of birth, and gender.
  • Contact Data includes billing address, delivery address, email address and telephone numbers.
  • Financial Data includes banking details of clients, suppliers, and agents for the making of payments by us and to us in relation to the services we provide.
  • Transaction Data includes details of products and services you have received or purchased from us and/or affiliates.
  • Technical Data includes internet protocol (“IP”) address, your login data, browser type and version, time zone setting and location, browser plug-in types and versions, operating system and platform, and other technology on the devices you use to access this website.
  • Profile Data includes your username and password, purchases or orders made by you, your interests, preferences, feedback, and survey/questionnaire responses.
  • Usage Data includes information about how you use our website, products, and services.
  • Marketing and Communications Data includes your preferences in receiving marketing from us and/or affiliates. 
  • Health Data includes information in relation to any aspect of your health and/or consequences of taking part in any clinical trials organized by our clients.

We may also collect, use and share Aggregated Data such as general statistical or demographic data for any purpose. Aggregated Data may be derived from your personal data but is not considered personal data in law as this data does not directly or indirectly reveal your identity. For example, we may aggregate your Usage Data to calculate the percentage of users accessing a specific website feature. However, if we combine or connect Aggregated Data with your personal data so that it can directly or indirectly identify you, we treat the combined data as personal data which will be used in accordance with this privacy policy.

Apart from Health Data and industry-wide or governmental survey(s)/questionnaire(s) where we are obliged to take part, we do not normally collect any Special Categories of Personal Data about you (this includes details about your race or ethnicity, religious or philosophical beliefs, sex life, sexual orientation, political opinions, and trade union membership.)

2.1 IF YOU FAIL TO PROVIDE PERSONAL DATA  

Where we need to collect personal data by law, or under the terms of a contract we have with you and you fail to provide that data when requested, we may not be able to perform the contract we have or are trying to enter into with you (for example, to provide you with our services). In this case, we may have to cancel a product or service you have with us but we will notify you if this is the case at the time.

3.  HOW YOUR PERSONAL DATA IS COLLECTED  

We use different methods to collect the categories of data described above from and about you including through:

  • Direct interactions. You may give us your personal data by filling in forms or by corresponding with us by mail, phone, and email, or otherwise. This includes personal data you provide when you:
    • apply online or otherwise for our services or products;
    • contract to receive our services; or
    • request marketing material to be sent to you.
  • Automated technologies or interactions. As you interact with our website, we may automatically collect Technical Data about your equipment, browsing actions and patterns. We collect this personal data by using cookies, log files, and other similar technologies. We may also receive Technical Data about you if you visit other websites employing our cookies. This aggregate data gives a “macro-view” of the visitor traffic pattern and insight to what sections of the website users visits most. We use this information to determine what kind of technology is available on the visitors' computers so it can better serve them by utilizing more advanced technologies (e.g., Macromedia Flash). None of this information is linked to any Personal Information. 
    • We passively collect and log the following information from visitors to our site such as:
      • Browser type
      • IP Address
      • Domain Name
      • Access Time
      • Operating System
  • Third parties or publicly available sources. We may receive personal data about you from various third parties and public sources as set out below:
    • We may receive Technical Data from the following parties:
      • analytics providers such as Google;
      • advertising networks;
      • search information providers;
      • portals.
    • Contact and Transaction Data from providers of technical, payment and delivery services.
    • Identity and Contact Data from data brokers or aggregators.


4.  HOW WE USE AND DISCLOSE YOUR PERSONAL DATA  

We will only use your personal data when the law allows us to. Most commonly, we will use your personal data in the following circumstances:

  1. Where we need to perform the contract we are about to enter into or have entered into with you, or to perform other legal obligations.
  2. Where it is necessary for our legitimate interests (or those of a third party) and your interests and fundamental rights do not override those interests (this applies in the EEA and UK).
  3. Where we need to comply with a legal or regulatory obligation.

In the EEA, in relation to sending direct marketing communications to you via email or text message, we will only do so where (i) we have your express consent or (ii) you are an existing client. You have the right to withdraw consent to marketing at any time by contacting us.

4.1 PURPOSES FOR WHICH WE WILL USE YOUR PERSONAL DATA  

 We have set out below, in table format, a description of the ways we plan to use your personal data, and which of the legal basis we rely on to do so. We have also identified what our legitimate interests are, where appropriate. 

Note that we may process your personal data for more than one lawful ground depending on the specific purpose for which we are using your data. Please contact us if you need details about the specific legal ground we are relying on to process your personal data where more than one ground has been set out in the table below. 

Purpose/ActivityCategory of dataLawful basis for processing including basis of legitimate interest
To register you as a new customer(a) Identity
(b) Contact
Performance of a contract with you
To process and deliver services and/or perform contractual obligations for you, including collecting and recovering money owed to us(a) Identity
(b) Contact
(c) Financial
(d) Transaction
(e) Marketing and Communications
(a) Performance of a contract with you
(b) Necessary for our legitimate interests (to recover funds due to us)
To manage our relationship with you which will include:
(a) Notifying you about changes to our terms or privacy policy
(b) Asking you to leave a review or take a survey/questionnaire
(a) Identity
(b) Contact
(c) Profile
(d) Marketing and Communications
(a) Performance of a contract with you
(b) Necessary to comply with a legal obligation
(c) Necessary for our legitimate interests (to keep our records updated and to study how customers use our products/services)
To enable you to complete a survey/questionnaire(a) Identity
(b) Contact
(c) Profile
(d) Usage
(e) Marketing and Communications
(a) Performance of a contract with you
(b) Necessary for our legitimate interests (to study how customers use our products/services, to develop them and grow our business)
To consider whether you are eligible/suitable for taking part in a specific clinical trial, related clinical investigation, or clinical support program carried our clients(a) Identity
(b) Contact
(c) Health
(a) Necessary for our legitimate interests to develop our products/services
(b) Necessary in order to comply with contractual obligations with our end-clients
To administer and protect our business and this website (including troubleshooting, data analysis, testing, system maintenance, support, reporting, and hosting of data)(a) Identity
(b) Contact
(c) Technical
(a) Necessary for our legitimate interests (for running our business, provision of administration and IT services, network security, to prevent fraud and in the context of a business reorganization or group restructuring exercise)
(b) Necessary to comply with a legal obligation
(c) Necessary to resolve disputes
To deliver relevant website content and advertisements to you and measure or understand the effectiveness of the advertising we serve to you(a) Identity
(b) Contact
(c) Profile
(d) Usage
(e) Marketing and Communications
(f) Technical
Necessary for our legitimate interests (to study how customers use our products/services, to develop them, to grow our business and to inform our marketing strategy)
To use data analytics to improve our website, products/services, marketing, customer relationships and experiences; provide audit record for consent(a) Technical
(b) Usage
Necessary for our legitimate interests (to define types of customers for our products and services, to keep our website updated and relevant, to develop our business and to inform our marketing strategy)
To make suggestions and recommendations to you about goods or services that may be of interest to you(a) Identity
(b) Contact
(c) Technical
(d) Usage
(e) Profile
Necessary for our legitimate interests (to develop our products/services and grow our business)
To comply with legal obligations, including proper government investigations, subpoenas, or other legal process or as otherwise necessary to prevent physical or financial harm or to prevent crime and fraud (a) Identity
(b) Contact
(c) Technical
(d) Usage
(e) Profile
(a) Necessary for our legitimate interests (to protect our business, employees, customers, and the public) 
(b) Necessary to comply with a legal obligation
(c) Necessary to resolve disputes

4.2 DISCLOSING INFORMATION TO THIRD-PARTIES  

We generally do not share your personal clinical data with any company outside CTM except for our trusted clients and service providers where needed for investigations and trials.

No mobile information will be shared with third parties/affiliates for marketing/promotional purposes. All the above categories exclude text messaging originator opt in data and consent; this information will not be shared with any third parties.

We may have to share your personal data with the parties set out below for the purposes set out in the table in section 4.1 above.

  • Third party sub-contractors who provide services for us and/or help to provide services to you. In the event that we use sub-contractors who have access to your personal data, we ensure that there are strict contractual terms in place to ensure that they only process personal data to the extent that we instruct them to do so in writing and there are suitably worded confidentiality and data protection clauses in all such contracts.
  • Third parties to whom we may choose to sell, transfer, or merge parts of our business or our assets. Alternatively, we may seek to acquire other businesses or merge with them. If a change of control arises in relation to our business, then the new owners may use your personal data in the same way as set out in this privacy policy.
  • We may disclose personal information to law enforcement, government authorities or otherwise in response to legal subpoenas or process as required by applicable law or in circumstances involving the possibility of physical or financial harm, fraud, or crime.

We require all third parties to respect the security of your personal data and to treat it in accordance with the law. We do not allow our third-party service providers to use your personal data for their own purposes and only permit them to process your personal data for specified purposes and in accordance with our instructions.

We do not sell your personal data to any third party. Our use and disclosure of Personal Identifiable Health Information (PIHI”) is limited to the minimum amount of personal data needed to accomplish the intended purpose of the specific clinical investigation or clinical trial and is used in relation to pre-screening activities for such clinical research projects. This includes using study questionnaires that only ask health and medical related questions that are directly associated with the relevant clinical research project as specified in approved protocols.

PIHI will generally not be used by us or disclosed by us to any third parties unless we have clear consent from you to do so.

Exceptionally, PIHI may be disclosed by us where we are required to do so by a relevant law or regulation. In particular, this includes, but is not limited to, situations where we are required to disclose such PIHI in relation to requests by public authorities to meet national security or law enforcement requirements. This will include use and/or disclosure in order to:

  • prevent or control disease, injury or disability;
  • report disease, injury or disability;
  • assist public health surveillance, investigations or interventions;
  • report child abuse or neglect or domestic violence;
  • avert a serious threat to individual(s) or public health or safety;
  • to coroners and/or medical examiners or for tissue donation;
  • in response to legal proceedings and relevant court orders or subpoenas;
  • for specialized government functions and worker’s compensation;
  • by workforce members who are whistle-blowers or victims of a criminal act;
  • when we believe in good faith that disclosure is necessary to protect our rights or to protect your safety, the safety of others or investigate fraud.

4.3 OPTING OUT  

You can ask us or third parties to stop sending you information/reminder messages at any time by contacting us.

Where you opt out of receiving these information/reminder messages, this will not apply to personal data provided to us as a result of a product/service purchase, warranty registration, product/service experience or other transactions.

4.4 COOKIES  

We only use cookies to record user-specific information on what pages users’ access or visit, record past activity, and session management and personalization. Use of cookies allows a better user experience when visitors return to the website. 

You can set your browser to refuse all or some browser cookies, or to alert you when websites set or access cookies. If you disable or refuse cookies, please note that some parts of the website may become inaccessible or not function properly.

4.4.1 Cookie Control. CTM’s interactive cookie statement clearly states how the user’s behavior is tracked and offers easy-to-use controls for granting and revoking consent. The user has the control to prevent cookies from being placed on their computer until consent via an affirmative act.

4.5 CHANGE OF PURPOSE  

We will only use your personal data for the purposes for which we collected it, unless we reasonably consider that we need to use it for another reason and that reason is compatible with the original purpose. 

If we need to use your personal data for an unrelated purpose, we will notify you and we will explain the legal basis which allows us to do so.

Please note that we may process your personal data without your knowledge or consent, in compliance with the above rules, where this is required or permitted by law.

4.6 USE OF HEALTH DATA IN THE UNITED STATES

The Health Insurance Portability and Accountability Act of 1996 (HIPAA”) and subsequent regulations published by the Department of Health and Human Services (“DHHS”) impose restrictions on other organizations (Covered Entities) which may be covered under HIPAA with respect to your relationship with CTM. CTM may, in providing subject recruiting call center services for one of these organizations, be required to comply with certain aspects of HIPAA in their conduct of human subject research activities.

Although CTM is not a Covered Entity as defined in the HIPAA privacy regulations, our policies and procedures, which govern the privacy rights of research participants included in this privacy policy, are compatible with those required by HIPAA for Covered Entities and will become standard for research activities involving PIHI.

All PIHI data collected by CTM in connection with subject recruiting for a clinical research study is captured electronically and transmitted through a secure network connection to a secure database. CTM’s data security policies are consistent with Good Clinical Practices, HIPAA and GDPR standards. CTM maintains separate Security Policies for Physical Security, Network Security and Application Security.

5.  INTERNATIONAL TRANSFERS  

Some personal data may be held on servers in the US. This will involve transferring your data outside the European Economic Area (“EEA”) or the UK. In addition, we use third parties who have IT servers located in the United States which hold your personal data. You consent to the transfer of your personal information to the United States. 

Whenever we transfer and/or process your personal data outside of the EEA or UK, we ensure a similar degree of protection is afforded to it by using specific contracts approved by the European Commission (or UK ICO) which give personal data the same protection it has in Europe.

6.  DATA SECURITY  

We and our third party hosting partners have put in place appropriate security measures to prevent your personal data from being accidentally lost, used or accessed in an unauthorized way, altered or disclosed. In addition, we limit access to your personal data to those employees, agents, contractors and other third parties who have a business need to know. They will only process your personal data on our instructions and they are subject to a duty of confidentiality.

We have put in place procedures to deal with any suspected personal data breach and will notify you and any applicable regulator of a breach where we are legally required to do so.

7.  DATA RETENTION  

We will only retain your personal data for as long as necessary to fulfill the purposes we collected it for, including for the purposes of satisfying any legal, accounting, or reporting requirements.

To determine the appropriate retention period for personal data, we consider the amount, nature, and sensitivity of the personal data, the potential risk of harm from unauthorized use or disclosure of your personal data, the purposes for which we process your personal data and whether we can achieve those purposes through other means, and the applicable legal requirements.

In some circumstances in the EEA and UK you can ask us to delete your data: see the section below entitled “Your Data Privacy Rights Under GDPR and UK Privacy Law” for further information.

We may also anonymize your personal data (so that it can no longer be associated with you) for research or statistical purposes in which case we may use this information indefinitely without further notice to you.

8.  YOUR DATA PRIVACY RIGHTS UNDER GDPR AND UK PRIVACY LAW

Under certain circumstances in the EEA and UK, you have the following rights under data protection laws in relation to your personal data:

Request access to your personal data (commonly known as a “data subject access request”). This enables you to receive a copy of the personal data we hold about you and to check that we are lawfully processing it.

Request correction of the personal data that we hold about you. This enables you to have any incomplete or inaccurate data we hold about you corrected, though we may need to verify the accuracy of the new data you provide to us.

Request erasure of your personal data. This enables you to ask us to delete or remove personal data where there is no good reason for us continuing to process it. You also have the right to ask us to delete or remove your personal data where you have successfully exercised your right to object to processing (see below), where we may have processed your information unlawfully or where we are required to erase your personal data to comply with local law. Note, however, that we may not always be able to comply with your request of erasure for specific legal reasons which will be notified to you, if applicable, at the time of your request.

Object to processing of your personal data where we are relying on a legitimate interest (or those of a third party) and there is something about your particular situation which makes you want to object to processing on this ground as you feel it impacts on your fundamental rights and freedoms. You also have the right to object where we are processing your personal data for direct marketing purposes. In some cases, we may demonstrate that we have compelling legitimate grounds to process your information which override your rights and freedoms.

Request restriction of processing of your personal data. This enables you to ask us to suspend the processing of your personal data in the following scenarios: (a) if you want us to establish the data’s accuracy; (b) where our use of the data is unlawful but you do not want us to erase it; (c) where you need us to hold the data even if we no longer require it as you need it to establish, exercise or defend legal claims; or (d) you have objected to our use of your data but we need to verify whether we have overriding legitimate grounds to use it.

Request the transfer of your personal data to you or to a third party. We will provide to you, or a third party you have chosen, your personal data in a structured, commonly used, machine-readable format. Note that this right only applies to automated information which you initially provided consent for us to use or where we used the information to perform a contract with you.

Withdraw consent at any time where we are relying on consent to process your personal data. However, this will not affect the lawfulness of any processing carried out before you withdraw your consent. If you withdraw your consent, we may not be able to provide certain products or services to you. We will advise you if this is the case at the time you withdraw your consent.

If you wish to exercise any of the rights set out above, please contact us.

In the EEA, you have the right to make a complaint at any time to the relevant national supervisory authority. For example, in the UK this would be the Information Commissioner’s Office (“ICO”), the UK supervisory authority for data protection issues (www.ico.org.uk). We would, however, appreciate the chance to deal with your concerns before you approach one of the national supervisory authorities so please contact us in the first instance.

A list of Supervisory Authorities is available here:  http://ec.europa.eu/justice/data-protection/bodies/authorities/index_en.htm.  

8.1 NO FEE USUALLY REQUIRED  

You will not have to pay a fee to access your personal data or to exercise any of the other rights. 

8.2 WHAT WE MAY NEED FROM YOU  

We may need to request specific information from you to help us confirm your identity and ensure your right to access your personal data (or to exercise any of your other rights). This is a security measure to ensure that personal data is not disclosed to any person who has no right to receive it. We may also contact you to ask you for further information in relation to your request to speed up our response.

8.3 TIME LIMIT TO RESPOND  

We try to respond to all legitimate requests within 30 business days. Occasionally it may take us longer than 30 business days if your request is particularly complex or you have made a number of requests. In this case, we will notify you and keep you updated.

9.  YOUR CALIFORNIA PRIVACY RIGHTS

If you are a resident of California, you have the following rights with respect to your Personal Information 

  • The right to know what Personal Information we have collected, used, disclosed and sold about you. To submit a request to know, please contact us contact us. You also may designate an authorized agent to make a request for access on your behalf.
  • The right to request that we delete any Personal Information we have collected about you.  To submit a request for deletion, please contact us. You also may designate an authorized agent to make a request for deletion on your behalf.

When you exercise these rights and submit a proper request to us, we will verify your identity by asking you for identifying information such as your email address, telephone number, and/or information about your account with us. We also may use a third party verification provider to verify your identity. Please note that we are only required to honor such requests twice in a 12-month period. 

Your exercise of these rights will have no adverse effect on the price and quality of our goods or services.

For the 12-month period prior to the date of this Privacy Policy, CTM has not sold any Personal Information collected about you; nor does it have any plans to do so in the future.

10.  DEFINITIONS

EEA and UK

Legitimate Interest means, in the EEA or UK, the interest of our business in conducting and managing our business to enable us to give you the best service/product and the best and most secure experience. We make sure we consider and balance any potential impact on you (both positive and negative) and your rights before we process your personal data for our legitimate interests. We do not use your personal data for activities where our interests are overridden by the impact on you (unless we have your consent or are otherwise required or permitted to by law). You can obtain further information about how we assess our legitimate interests against any potential impact on you in respect of specific activities by contacting us.

Performance of Contract means processing your data where it is necessary for the performance of a contract to which you are a party or to take steps at your request before entering into such a contract.

Comply with a legal or regulatory obligation means processing your personal data where it is necessary for compliance with a legal or regulatory obligation that we are subject to.

GDPR is the European Union General Data Protection Regulation.

UNITED STATES

Covered Entity means an institution, organization or other entity that is subject to the rules of the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”). Covered Entities include: (i) a health plan, (ii) a healthcare clearinghouse and, (iii) a healthcare provider who transmits any personal identifiable health information in electronic form in connection with a transaction covered by HIPAA.

Personal Identifiable Health Information (“PIHI”) means any information including demographic information collected from an individual that:

  1. relates to (a) the past, present or future physical or mental health or condition of an individual; (b) the provision of healthcare to an individual; or (c) the past, present or future payment for the provision of healthcare to the individual; and
  1. identifies the individual or there is a reasonable basis to believe it can be used to identify the individual; and
  1. PIHI does not include education records or medical records covered by the Family Education Rights and Privacy Act or employment records held by CTM in its role as an employer.

CALIFORNIA

Personal Information means any information that identifies, relates to, describes, is reasonably capable of being associated with, or could reasonably be linked, directly or indirectly, with a particular consumer or household. 

FOR ANY JURISDICTION

Third Parties means: 

  • Service providers acting as processors and who provide services to us.
  • Professional advisers acting as processors or joint controllers including lawyers, bankers, auditors and insurers who provide consultancy, banking, legal, insurance and accounting services to us.
  • Regulators and other state authorities acting as processors or joint controllers in any jurisdiction in which we are operating and who require reporting of processing activities in certain circumstances.

Datos básicos sobre
la diabetes tipo 2 (DT2)

  • La diabetes es una afección que aparece cuando el cuerpo no produce suficiente insulina o cuando el cuerpo no puede usar de forma efectiva la insulina que produce.
  • Más de 422 millones de personas en todo el mundo tienen diabetes.12
  • Más del 95 % de las personas con diabetes tienen DT2.12
  • Los factores de riesgo para la DT2 incluyen los siguientes:13
  • Tener prediabetes
  • Tener sobrepeso
  • Tener 45 años o más
  • Tener un padre o hermano con DT2
  • Realizar actividad física menos de 3 veces a la semana
  • Sin tratamiento, la DT2 hace que el azúcar se acumule en la sangre, lo que, eventualmente, puede traer graves consecuencias, como las siguientes:14
  • Enfermedad cardíaca
  • Enfermedad renal
  • Ceguera
  • Amputación

Kilka faktów na
temat cukrzycy typu 2

  • Cukrzyca to choroba, która rozwija się, kiedy organizm nie wytwarza wystarczającej ilości insuliny lub nie jest w stanie skutecznie wykorzystać wytworzonej przez siebie insuliny.
  • Ponad 422 miliony ludzi na świecie choruje na cukrzycę12.
  • Ponad 95% osób chorych na cukrzycę ma cukrzycę typu 212.
  • Czynniki ryzyka cukrzycy typu 2 obejmują13:
  • stan przedcukrzycowy;
  • nadwagę;
  • ukończony 45 rok życia;
  • występowanie cukrzycy typu 2 u rodzica lub rodzeństwa;
  • uprawianie aktywności fizycznej rzadziej niż trzy razy w tygodniu.
  • Nieleczona cukrzyca typu 2 powoduje gromadzenie się cukru we krwi, co może prowadzić do poważnych konsekwencji, takich jak14:
  • choroba serca;
  • choroba nerek;
  • ślepota;
  • amputacje.

Información breve sobre
diabetes tipo 2 (DM2)

  • La diabetes es una afección que ocurre cuando el cuerpo no produce la cantidad suficiente de insulina, o bien cuando el cuerpo no logra utilizar de manera efectiva la insulina que sí produce.
  • Más de 422 millones de personas en el mundo padecen diabetes.12
  • Más del 95 % de las personas que padecen diabetes tienen DM2.12
  • Entre los factores de riesgo de la DM2, se encuentran los siguientes:13
  • padecer prediabetes;
  • tener exceso de peso;
  • tener 45 años o más;
  • tener un progenitor, un hermano o hermana con DM2;
  • realizar ejercicio físico menos de 3 veces por semana.
  • Sin tratamiento, la DM2 provoca que el azúcar se acumule en la sangre, y esto puede tener consecuencias graves como las siguientes:14
  • enfermedad cardíaca;
  • enfermedad renal;
  • ceguera;
  • amputación.

Quick Facts on
Type 2 Diabetes (T2D)

  • Diabetes is a condition that occurs when the body does not produce enough insulin, or when the body cannot effectively use the insulin it produces.
  • More than 422 million people worldwide have diabetes.12
  • More than 95% of the people who have diabetes have T2D.12
  • Risk factors for T2D include:13
  • Having prediabetes
  • Having excess weight
  • Being 45 years old or older
  • Having a parent or sibling with T2D
  • Being physically active less than 3 times per week
  • Without treatment, T2D causes sugar to build up in the blood, which can eventually lead to serious consequences such as:14
  • Heart disease
  • Kidney disease
  • Blindness
  • Amputation

Quelques faits en bref sur
le diabète de type 2 (DT2)

  • Le diabète est une maladie qui survient lorsque le corps ne produit pas assez d’insuline ou lorsque le corps ne peut pas utiliser efficacement l’insuline qu’il produit.
  • Plus de 422 millions de personnes dans le monde sont atteintes de diabète.12
  • Plus de 95 % des personnes atteintes de diabète ont le DT2.12
  • Les facteurs de risque de DT2 comprennent ce qui suit :13
  • Être atteint de prédiabète
  • Présenter un surpoids
  • Être âgé de 45 ans ou plus
  • Avoir un parent, un frère ou une sœur atteint du DT2
  • Pratiquer une activité physique moins de 3 fois par semaine
  • Sans traitement, le DT2 provoque une accumulation de glucose dans le sang, ce qui peut avoir des conséquences graves telles que :14
  • une maladie cardiaque
  • une maladie rénale
  • la cécité
  • une amputation

Datos básicos sobre
la osteoartritis

  • La osteoartritis (OA) es la forma más frecuente de artritis, la cual se presenta como una inflamación e hinchazón de las articulaciones. La OA aparece cuando el cartílago dentro de una articulación comienza a deteriorarse y provocar cambios en el hueso subyacente. Los cambios pueden comenzar lentamente y empeorar con el tiempo.9
  • La OA suele encontrarse en las manos, las caderas y las rodillas.9
  • Los factores de riesgo para la OA incluyen los siguientes:9
  • Edad (el riesgo aumenta con la edad)
  • Sexo (las mujeres tienen más probabilidades de desarrollar OA)
  • Sobrepeso
  • Genética
  • Los síntomas de la OA incluyen los siguientes:9
  • Dolor o molestias
  • Rigidez musculoesquelética
  • Disminución en el rango de movimiento
  • Hinchazón
  • Desde 1990, ha habido un aumento del 113 % en OA alrededor del mundo. En 2019, hubo más de 527 millones casos.10
  • Los estudios basados en la población han demostrado de forma consistente un vínculo entre el sobrepeso o la obesidad y la OA de rodilla.11
  • Los estudios han demostrado que la pérdida de peso podría mejorar el dolor y la función en pacientes con OA de rodilla.11

Kilka faktów na
temat choroby zwyrodnieniowej stawów

  • Choroba zwyrodnieniowa stawów (ChZS) to najczęstsza postać zapalenia stawów, czyli stanu zapalnego i obrzęku stawów. ChZS rozwija się, kiedy chrząstka stawowa zaczyna ulegać zniszczeniu, co powoduje zmiany w znajdujących się pod nią kościach. Zmiany te mogą powoli nasilać się z czasem9.
  • ChZS najczęściej dotyka rąk, bioder i kolan9.
  • Czynniki ryzyka ChZS obejmują9:
  • wiek (ryzyko zwiększa się z wiekiem);
  • płeć (u kobiet ChZS rozwija się częściej);
  • nadwagę;
  • predyspozycje genetyczne.
  • Objawy ChZS obejmują9:
  • ból;
  • sztywność;
  • ograniczony zakres ruchu;
  • obrzęk.
  • Od roku 1990 częstość występowania ChZS na świecie wzrosła o 113%. W roku 2019 stwierdzono ponad 527 milionów przypadków10.
  • Badania populacyjne konsekwentnie wskazują na istnienie związku pomiędzy nadwagą i otyłością a chorobę zwyrodnieniową stawu kolanowego11.
  • Badania wykazały, że obniżenie masy ciała może zmniejszyć ból i poprawić funkcjonowanie u osób z chorobą zwyrodnieniową stawu kolanowego11.

Información breve sobre
la osteoartritis

  • La osteoartritis (OA) es el tipo más común de artritis, que es la inflamación e hinchazón de las articulaciones. La OA ocurre cuando el cartílago que se encuentra entre las articulaciones comienza a deteriorarse y causa cambios en los huesos que están debajo. Dichos cambios pueden comenzar de forma lenta y agravarse con el paso del tiempo.9
  • En particular, la OA se presenta en las manos, la cadera y las rodillas.9
  • Entre los factores de riesgo de la OA, se encuentran los siguientes:9
  • edad (el riesgos aumenta con la edad);
  • género (las mujeres son más propensas a desarrollar OA);
  • exceso de peso;
  • factores genéticos.
  • Entre los síntomas de la OA, se incluyen los siguientes:9
  • dolor;
  • rigidez musculoesquelética;
  • disminución de la movilidad;
  • hinchazón.
  • Desde 1990, se ha observado un incremento del 113 % en los casos de OA a nivel mundial. In 2019, se registraron más de 527 millones de casos.10
  • Estudios basados en la población han demostrado, de modo consistente, que existe una relación entre el exceso de peso o la obesidad y la OA de rodilla.11
  • Los estudios han demostrado que la pérdida de peso puede ayudar a mejorar el dolor y la movilidad en pacientes con OA de rodilla.11

Quick Facts on
Osteoarthritis

  • Osteoarthritis (OA) is the most common form of arthritis, which is inflammation and swelling in the joints. OA happens when the cartilage within a joint starts to break down and cause changes to the underlying bone. The changes may begin slowly and get worse over time.9
  • OA is typically found in the hands, hips, and knees.9
  • Risk factors for OA include:9
  • Age (risk increases with age)
  • Gender (women are more likely to develop OA)
  • Excess weight
  • Genetics
  • Symptoms of OA include:9
  • Pain or aching
  • Stiffness
  • Decreased range of motion
  • Swelling
  • Since 1990, there has been a 113% increase in OA around the world. In 2019, there were more than 527 million cases.10
  • Population-based studies have consistently shown a link between excess weight or obesity and knee OA.11
  • Studies have shown that weight loss may improve pain and function in patients with knee OA.11

Quelques faits en bref sur
l’arthrose

  • L’arthrose est la forme la plus courante d’arthrite, qui est l’inflammation et le gonflement des articulations. L’arthrose se produit lorsque le cartilage d’une articulation commence à se décomposer et à provoquer des changements dans l’os sous-jacent. Les changements peuvent commencer lentement et empirer avec le temps.9
  • L’arthrose touche généralement les mains, les hanches et les genoux.9
  • Les facteurs de risque d’arthrose comprennent ce qui suit :9
  • L’âge (le risque augmente avec l’âge)
  • Le sexe (les femmes sont plus susceptibles de développer de l’arthrose)
  • Le surpoids
  • La génétique
  • Les symptômes d’arthrose peuvent comprendre ce qui suit :9
  • La douleur, passagère ou continue
  • La raideur
  • La diminution de l’amplitude des mouvements
  • Le gonflement
  • Depuis 1990, il y a eu une augmentation de 113 % de l’arthrose dans le monde. En 2019, il y a eu plus de 527 millions de cas.10
  • Des études sur la population ont constamment montré un lien entre le surpoids ou l’obésité et l’arthrose du genou.11
  • Des études ont montré que la perte de poids peut réduire la douleur et améliorer la fonction chez les patients atteints d’arthrose du genou.11

Datos básicos sobre
la apnea obstructiva del sueño

  • La apnea obstructiva del sueño (AOS) aparece cuando las vías respiratorias superiores se bloquean muchas veces mientras duerme, lo que reduce o detiene el flujo de aire. Esto significa que su respiración se detiene por breves periodos de tiempo.6
  • Las personas con amígdalas agrandadas, sobrepeso o cambios en los niveles hormonales podrían tener un mayor riego de AOS.6
  • Los síntomas de la AOS incluyen los siguientes:6
  • Ronquidos
  • Cefaleas matutinas
  • Somnolencia diurna crónica
  • Fatiga
  • Irritabilidad
  • Concentración deteriorada
  • La AOS es bastante frecuente; los estudios estiman que casi 1 de cada 5 hombres y casi 1 de cada 6 mujeres se ven afectados.7
  • Los estudios han revelado que la pérdida de peso podría mejorar los síntomas de la AOS.8

Kilka faktów na
temat obturacyjnego bezdechu sennego

  • Obturacyjny bezdech senny ma miejsce wówczas, gdy górne drogi oddechowe są blokowane wielokrotnie podczas snu, co ogranicza lub uniemożliwia przepływ powietrza. Oznacza to, ze oddech ustaje na krótkie okresy czasu6.
  • Osoby z dużymi migdałkami, nadwagą oraz zaburzeniami hormonalnymi są narażone na większe ryzyko obturacyjnego bezdechu sennego6.
  • Objawy obturacyjnego bezdechu sennego obejmują6:
  • chrapanie;
  • poranne bóle głowy;
  • przewlekłą senność w ciągu dnia;
  • zmęczenie;
  • drażliwość;
  • zaburzenia koncentracji.
  • Obturacyjny bezdech senny występuje dość często – badania wskazują, że niemal 1 na 5 mężczyzn i 1 na 6 kobiet cierpi na obturacyjny bezdech senny7.
  • Badania wykazały, że obniżenie masy ciała może złagodzić objawy obturacyjnego bezdechu sennego8.

Información breve sobre
la apnea obstructiva del sueño

  • La apnea obstructiva del sueño (AOS) ocurre cuando la vía aérea superior se bloquea en repetidas ocasiones durante el sueño, lo que reduce o detiene el paso de aire hacia los pulmones. Esto quiere decir que la respiración se detiene por breves periodos de tiempo.6
  • En personas con amígdalas grandes, exceso de peso o cambios hormonales, el riesgo de sufrir AOS es mayor.6
  • Entre los síntomas de la AOS, se incluyen los siguientes:6
  • ronquidos;
  • cefaleas matutinas;
  • somnolencia diurna crónica;
  • fatiga;
  • irritabilidad;
  • concentración deteriorada.
  • La AOS es bastante común: los estudios calculan que la padecen alrededor de 1 de cada 5 hombres, y 1 de cada 6 mujeres.7
  • Los estudios han demostrado que la pérdida de peso puede ayudar a mejorar los síntomas de la AOS.8

Quick Facts on
Obstructive Sleep Apnoea

  • Obstructive sleep apnoea (OSA) happens when your upper airway becomes blocked many times during sleep, which reduces or stops airflow. This means that your breathing stops for brief periods.6
  • Those with large tonsils, excess weight, or changes in hormone levels may be at increased risk for OSA.6
  • Symptoms of OSA include:6
  • Snoring
  • Morning headaches
  • Chronic daytime sleepiness
  • Fatigue
  • Irritability
  • Impaired concentration
  • OSA is fairly common—studies estimate that almost 1 in every 5 men, and almost 1 in every 6 women are affected.7
  • Studies have shown that weight loss may improve symptoms of OSA.8

Quelques faits en bref sur
l’apnée obstructive du sommeil

  • L’apnée obstructive du sommeil (AOS) se produit lorsque les voies respiratoires supérieures sont bloquées de nombreuses fois pendant le sommeil, ce qui réduit ou interrompt le flux d’air. Cela signifie que la respiration s’arrête pendant de courtes périodes.6
  • Les personnes présentant de grosses amygdales, un surpoids ou des changements hormonaux peuvent être exposées à un risque accru d’AOS.6
  • Les symptômes d’AOS incluent ce qui suit:6
  • Le ronflement
  • Les céphalées matinales
  • La somnolence diurne chronique
  • La fatigue
  • L’irritabilité
  • La difficulté à se concentrer
  • L’AOS est assez fréquente – des études estiment que près d’un homme sur cinq et près d’une femme sur six sont touchés.7
  • Des études ont montré que la perte de poids peut améliorer les symptômes de l’AOS.8

Datos básicos sobre
las enfermedades cardiovasculares

  • Las enfermedades cardiovasculares son un grupo de afecciones que afectan al corazón y los vasos sanguíneos.3
  • Este grupo de enfermedades incluye las siguientes:
  • Enfermedad cardíaca coronaria3
  • Enfermedad cerebrovascular3
  • Enfermedad arterial periférica3
  • Insuficiencia cardíaca4
  • Los ataques al corazón y los ictus suelen ser causados por un bloqueo que evita que el corazón o el cerebro reciban el suministro de sangre que necesitan. Los ataques cardíacos e ictus se denominan eventos agudos porque son repentinos y graves cuando comienzan.3
  • Las enfermedades cardiovasculares son la causa principal de muerte a nivel mundial. En 2019, casi 1 de cada 3 personas murió a causa de una enfermedad cardiovascular.3
  • Los factores de riesgo de enfermedades cardiovasculares incluyen los siguientes:
  • Dieta no saludable
  • Falta de actividad física
  • Consumo de tabaco
  • Consumo dañino de alcohol3
  • Presión arterial alta5
  • Colesterol alto5

Kilka faktów na
temat chorób układu krążenia

  • Choroby układu krążenia to grupa chorób dotykających serca i naczyń krwionośnych3.
  • Ta grupa chorób obejmuje:
  • chorobę niedokrwienną serca3
  • chorobę naczyniową mózgu3
  • chorobę tętnic obwodowych3
  • niewydolność serca4
  • Zawały serca i udary są zwykle spowodowane blokadą, która uniemożliwia doprowadzenie odpowiedniej ilości krwi do serca lub mózgu. Zawały serca i udary są nazywane zdarzeniami ostrymi, ponieważ występują nagle i mają ciężki przebieg3.
  • Choroby układu krążenia są główną przyczyną śmierci na świecie. W roku 2019 niemal 1 osoba na 3 umarła z powodu choroby układu krążenia3.
  • Czynniki ryzyka chorób układu krążenia obejmują:
  • niezdrową dietę;
  • brak aktywności fizycznej;
  • palenie tytoniu;
  • nadużywanie alkoholu3;
  • wysokie ciśnienie krwi5;
  • wysoki poziom cholesterolu5.

Información breve sobre
enfermedad cardiovascular

  • La enfermedad cardiovascular comprende una serie de problemas que afectan al corazón y a los vasos sangüíneos.3
  • En este grupo de enfermedades, se incluyen las siguientes:
  • Enfermedad coronaria3
  • Enfermedad cerebrovascular3
  • Enfermedad arterial periférica3
  • Fallo cardíaco4
  • Los infartos y los accidentes cerebrovasculares suelen ocurrir por un bloqueo que impide que el corazón o el cerebro reciban el flujo sanguíneo que necesitan. Los infartos y los accidentes cerebrovasculares se denominan eventos agudos, ya que se caracterizan por un inicio grave y repentino.3
  • La enfermedad cardiovascular es la principal causa de muerte a nivel mundial. En 2019, alrededor de 1 de cada 3 personas murieron debido a una enfermedad cardiovascular.3
  • Entre los factores de riesgo de las enfermedades cardiovasculares, se encuentran los siguientes:
  • dieta no saludable;
  • sedentarismo;
  • consumo de tabaco;
  • consumo excesivo de alcohol;3
  • presión arterial alta;5
  • colesterol alto.5

Quick Facts on
Cardiovascular Disease

  • Cardiovascular disease is a group of conditions that affect the heart and blood vessels.3
  • This group of diseases includes:
  • Coronary heart disease3
  • Cerebrovascular disease3
  • Peripheral arterial disease3
  • Heart failure4
  • Heart attacks and strokes are usually caused by a blockage that prevents the heart or brain from receiving the blood flow it needs. Heart attacks and strokes are called acute events because they are sudden and severe when they begin.3
  • Cardiovascular disease is the leading cause of death globally. In 2019, almost 1 in 3 people died from cardiovascular disease.3
  • Risk factors for cardiovascular disease include:
  • Unhealthy diet
  • Physical inactivity
  • Tobacco use
  • Harmful use of alcohol3
  • High blood pressure5
  • High cholesterol5

Quelques faits en bref sur
les maladies cardiovasculaires

  • Les maladies cardiovasculaires sont un groupe de maladies qui affectent le cœur et les vaisseaux sanguins.3
  • Ce groupe de maladies comprend les suivantes :
  • La coronaropathie3
  • La maladie cérébrovasculaire3
  • La maladie artérielle périphérique3
  • L’insuffisance cardiaque4
  • Les crises cardiaques et les accidents vasculaires cérébraux sont généralement causés par un blocage qui empêche le cœur ou le cerveau de recevoir le flux sanguin dont il a besoin. Les crises cardiaques et les accidents vasculaires cérébraux sont appelés « événements aigus » parce qu’ils sont soudains et graves quand ils se produisent.3
  • Les maladies cardiovasculaires sont la principale cause de mort dans le monde. En 2019, près d’une personne sur trois est décédée d’une maladie cardiovasculaire.3
  • Les facteurs de risque des maladies cardiovasculaires comprennent ce qui suit :
  • Une alimentation malsaine
  • Une inactivité physique
  • La consommation de tabac
  • La consommation nocive d’alcool3
  • Une pression artérielle élevée5
  • Un taux de cholestérol élevé5

Puntos claves de la
diabetes tipo 2 (DT2)

  • La diabetes es una afección que aparece cuando el cuerpo no produce suficiente insulina o cuando no puede utilizar de forma eficaz la insulina que produce.
  • Más de 422 millones de personas en todo el mundo tienen diabetes.12
  • Más del 95 % de las personas con diabetes tiene DT2.12
  • Los factores de riesgo de la DT2 incluyen los siguientes:13
  • Prediabetes
  • Sobrepeso
  • Tener 45 años o más
  • Tener padres o hermanos con DT2
  • Realizar actividad física menos de 3 veces a la semana
  • Sin tratamiento, la DT2 genera una acumulación de azúcar en la sangre, que, con el tiempo, puede tener consecuencias graves como las siguientes:14
  • Enfermedad cardiaca
  • Enfermedad renal
  • Ceguera
  • Amputación

Puntos clave de la
osteoartritis

  • La osteoartritis (OA) es la forma más frecuente de artritis, que es la inflamación e hinchazón de las articulaciones. La OA se da cuando el cartílago dentro de la articulación comienza a romperse y produce cambios en el hueso subyacente. Estos cambios pueden comenzar de a poco y empeorar con el tiempo.9
  • La OA suele darse en las manos, la cadera y las rodillas.9
  • Entre los factores de riesgo de la OA se incluyen los siguientes:9
  • Edad (el riesgo aumenta con el paso de los años)
  • Sexo (las personas de sexo femenino tienen más probabilidades de desarrollar OA)
  • Sobrepeso
  • Genética
  • Algunos síntomas de la OA incluyen los siguientes:9
  • Dolor o sensibilidad
  • Rigidez
  • Movilidad disminuida
  • Hinchazón
  • Desde 1990, los casos de OA han aumentado un 113 % en todo el mundo. En 2019, hubo más de 527 millones de casos.10
  • Los estudios sobre la población muestran de manera consistente una relación entre el sobrepeso o la obesidad y la OA de rodilla.11
  • Los estudios muestran que la pérdida de peso puede mejorar el dolor y la función en los pacientes con OA de rodilla.11

Puntos clave de la
obstructiva del sueño

  • La apnea obstructiva del sueño (AOS) se genera cuando las vías respiratorias superiores se bloquean varias veces mientras duerme, lo que reduce o impide el flujo de aire. Esto quiere decir que deja de respirar durante períodos breves.6
  • Las personas con amígdalas grandes, sobrepeso o cambios en los niveles hormonales pueden tener un mayor riesgo de tener AOS.6
  • Algunos síntomas de la AOS incluyen los siguientes:6
  • Ronquidos
  • Dolor de cabeza durante las mañanas
  • Somnolencia diurna crónica
  • Fatiga
  • Irritabilidad
  • Concentración deteriorada
  • La AOS es bastante frecuente; los estudios estiman que casi 1 de cada 5 hombres y casi 1 de cada 6 mujeres la tienen.7
  • Los estudios demuestran que la pérdida de peso puede mejorar los síntomas de la AOS.8

Puntos clave de la
enfermedad cardiovascular

  • La enfermedad cardiovascular abarca un grupo de enfermedades que afectan al corazón y a los vasos sanguíneos.3
  • Este grupo de enfermedades incluye las siguientes:
  • Enfermedad coronaria3
  • Enfermedad cerebrovascular3
  • Enfermedad arterial periférica3
  • Fallo cardiaco4
  • Los ictus y ataques al corazón suelen ser el resultado de un bloqueo que evita que el corazón o el cerebro reciba el flujo sanguíneo que necesita. Se los llama acontecimientos agudos porque son repentinos y graves desde su inicio.3
  • La enfermedad cardiovascular es la principal causa de muerte a nivel mundial. En el año 2019, casi 1 de cada 3 personas murió a causa de la enfermedad cardiovascular.3
  • Los factores de riesgo de la enfermedad cardiovascular incluyen los siguientes:
  • Dieta no saludable
  • Inactividad física
  • Consumo de tabaco
  • Consumo dañino de alcohol3
  • Presión arterial alta5
  • Colesterol alto5

Quick Facts on
Type 2 Diabetes (T2D)

  • Diabetes is a condition that occurs when the body does not produce enough insulin, or when the body cannot effectively use the insulin it produces.
  • More than 422 million people worldwide have diabetes.12
  • More than 95% of the people who have diabetes have T2D.12
  • Risk factors for T2D include:13
  • Having prediabetes
  • Having excess weight
  • Being 45 years old or older
  • Having a parent or sibling with T2D
  • Being physically active less than 3 times per week
  • Without treatment, T2D causes sugar to build up in the blood, which can eventually lead to serious consequences such as:14
  • Heart disease
  • Kidney disease
  • Blindness
  • Amputation

Quick Facts on
Osteoarthritis

  • Osteoarthritis (OA) is the most common form of arthritis, which is inflammation and swelling in the joints. OA happens when the cartilage within a joint starts to break down and cause changes to the underlying bone. The changes may begin slowly and get worse over time.9
  • OA is typically found in the hands, hips, and knees.9
  • Risk factors for OA include:9
  • Age (risk increases with age)
  • Gender (women are more likely to develop OA)
  • Excess weight
  • Genetics
  • Symptoms of OA include:9
  • Pain or aching
  • Stiffness
  • Decreased range of motion
  • Swelling
  • Since 1990, there has been a 113% increase in OA around the world. In 2019, there were more than 527 million cases.10
  • Population-based studies have consistently shown a link between excess weight or obesity and knee OA.11
  • Studies have shown that weight loss may improve pain and function in patients with knee OA.11

Quick Facts on
Obstructive Sleep Apnea

  • Obstructive sleep apnea (OSA) happens when your upper airway becomes blocked many times during sleep, which reduces or stops airflow. This means that your breathing stops for brief periods.6
  • Those with large tonsils, excess weight, or changes in hormone levels may be at increased risk for OSA.6
  • Symptoms of OSA include:6
  • Snoring
  • Morning headaches
  • Chronic daytime sleepiness
  • Fatigue
  • Irritability
  • Impaired concentration
  • OSA is fairly common—studies estimate that almost 1 in every 5 men, and almost 1 in every 6 women are affected.7
  • Studies have shown that weight loss may improve symptoms of OSA.8

Quick Facts on
Cardiovascular Disease

  • Cardiovascular disease is a group of conditions that affect the heart and blood vessels.3
  • This group of diseases includes:
  • Coronary heart disease3
  • Cerebrovascular disease3
  • Peripheral arterial disease3
  • Heart failure4
  • Heart attacks and strokes are usually caused by a blockage that prevents the heart or brain from receiving the blood flow it needs. Heart attacks and strokes are called acute events because they are sudden and severe when they begin.3
  • Cardiovascular disease is the leading cause of death globally. In 2019, almost 1 in 3 people died from cardiovascular disease.3
  • Risk factors for cardiovascular disease include:
  • Unhealthy diet
  • Physical inactivity
  • Tobacco use
  • Harmful use of alcohol3
  • High blood pressure5
  • High cholesterol5

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website, you are giving us consent to collect cookies.